Incorporating cost-effectiveness data into a formulary plan helps shift the conversation from cost to value when considering which drugs to include.
As healthcare costs continue to rise, employer-sponsored health plans increasingly are faced with the challenge of managing cost without limiting access to high-value treatments essential to maintain health for their members.
To balance net clinical benefit with treatment cost, health plans should consider including cost-effectiveness data in their formulary review process, according to John Watkins, PharmD, pharmacy manager of Formulary Development for Premera Blue Cross in Mountlake Terrace, Washington.
Incorporating cost-effectiveness data into a formulary plan helps shift the conversation from cost to value when considering which drugs to include, explained Watkins, speaking at the Academy of Managed Care Pharmacy (AMCP) meeting during a session entitled Pharmacoeconomic Modeling: Applying Value to Formulary Management. The value-based formulary benefits offer a scientific and nuanced approach to achieving the balance between net clinical benefits and treatment cost, he emphasized.
To illustrate the benefit of including value-based formulary in a health plan, Kai Yeung, PharmD, a University of Washington student who is evaluating Premera’s project for his doctoral dissertation, walked participants through a pilot program using a value-based formulary designed by Premera Blue Cross implemented in 2010. The pilot program was implemented because of the almost 10% increase in pharmacy benefit costs projected over the next year if the health plan remained using the existing three-tier payment structure.
Using the value-based formulary, members were moved to a four-tier design that added a preventive tier that required no copayment along with four tiers in which copays were substantially increased.
Although this resulted in a 10% cost share increase to all members, those with chronic conditions including hypertension, diabetes, and hypercholesterolemia had considerably lower average increases.
Overall, using the value-based formulary resulted in an 11% reduction from projected pharmacy costs for the health plan with generally no significant impact on medication use and adherence.
According to Yeung, early evaluations of the pilot program suggest that value-based formulary is associated with lower total drug spending and that despite the overall increase in copays for diabetes, hypertension, and hypercholesterolemia, utilization of and adherence to drugs to treat these conditions were not negatively affected.
Although Watkins said that including cost-effectiveness data in the formulary review process may take some effort in the beginning, he encouraged managed care pharmacists to do so, saying they will be surprised at what they already know of “what is needed to critically appraise economic studies.”
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
With aging populations, osteoporosis rates are set to increase, and researchers are looking for the next innovative drug to help prevent or manage the bone disease as there is currently no drug that completely does so effectively, according to a recent study published in Advanced Science.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 26th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More